Introduction
In the ever-evolving landscape of microbiology and quality control, Rapid Microbial Methods (RMMs) have emerged as powerful tools for detecting and enumerating microorganisms in pharmaceutical manufacturing, food and beverage testing, and environmental monitoring. These innovative techniques offer faster results, increased sensitivity, and improved efficiency compared to traditional culture-based methods. However, before implementing an RMM in any facility, it is crucial to rigorously test and validate its performance using a diverse array of relevant microorganisms.
This article delves into the intricate process of testing RMMs with microorganisms, exploring the key considerations, challenges, and best practices that ensure the reliability and effectiveness of these methods. The Sievers Soleil Rapid Bioburden Analyzer is compared to plate methods using an appropriate selection of organisms, and critical parameters are evaluated to demonstrate the method’s accuracy, precision, and specificity. When evaluating an RMM, it is important to show equivalency to traditional methods using traditional Colony Forming Units (CFU). This proves that the results from the RMM are as reliable and meaningful as those obtained from traditional cultural methods but with the added benefit of faster Time to Results (TTR).
By understanding the nuances of testing RMMs with microorganisms, quality control professionals and microbiologists can make informed decisions about method adoption, optimize their testing protocols, and ultimately enhance the safety and quality of their products.
Methods
Microorganisms were chosen according to recommendations from the United States Pharmacopeia (USP) Chapter Validation of Alternative Microbiological Methods, European Pharmacopoeia Chapter 5.1.6: Alternative Methods for Control of Microbiological Quality, and Japanese Pharmacopoeia General Information: G4: Microbiological Examination of Non-sterile Products, specifically, the section titled “Rapid Microbial Methods”.
The microorganisms chosen for this study were as follows:
- A. brasiliensis
- B. cepacia
- B. diminuta
- B. subtilis
- C. albicans
- E. coli
- P. aeruginosa
- R. pickettii
- S. aureus
- S. enterica
- S. maltophilia
- Mixture: B. diminuta, R. pickettii, S. maltophilia, & B. cepacia
The microorganisms were made into a stock solution and placed in starving conditions for three days. The JP recommends using starved or stressed organisms when evaluating an RMM to simulate real-world conditions. To test the Precision and Linearity of the RMM in comparison to agar plates, serial dilutions were made of each stock solution. The concentrations tested were 0.05 CFU/mL, 0.1 CFU/mL, 1 CFU/mL, 10 CFU/mL, and 100 CFU/mL. Ten replicates of each of the 0.05 CFU/mL, 0.1 CFU/mL, and 1 CFU/mL were tested, and six replicates of the higher concentrations were tested (10 CFU/mL and 100 CFU/mL) on the Sievers Soleil Rapid Bioburden Analyzer. Organisms were added to Water For Cell Culture in 250 mL bottles and then aliquoted out to be tested on the Soleil and by membrane filtration.
Negative control samples were tested throughout the study. Additionally, System Suitability standards were run at two different concentrations during the daily start-up.
Acceptance Criteria
Linearity: >0.95 per USP <1223>
Accuracy and Precision: Recovery compared to the agar plates >50% and a goal of <200%
System Suitability Standards: Standard 1 ± 5 beads/mL; Standard 2 ± 10 beads/mL
Negative Controls: < 10 CFU/ 100 mL
Results
The Lower Limit of Quantification was determined to be 0.1 CFU/ mL across all organisms. The average percent recovery was 140.9%, passing the acceptance criteria.
The Linearity across all organisms was determined for 4 logs and 3 logs. See Table 1 for the results.
Accuracy
The acceptance criteria for the Accuracy of the Soleil RMM platform was >50% with a goal of <200%. Table 2 shows the recovery compared to traditional methods for all microorganisms and the mixture.
Conclusion
When evaluating RMMs, it’s important to perform testing in your facility that utilizes multiple different microorganisms. The conditions in which to grow the organisms and maintain stock solutions are important to imitate real-world conditions. Microorganisms should be chosen based on the pharmacopoeia, but also based on common organisms found in your facility.
The Sievers Soleil Rapid Bioburden Analyzer represents a significant advancement in bioburden testing technology. Its combination of speed, performance, sensitivity, and broad application makes it a powerful tool for microbiological analysis in various industries.
The analyzer’s ability to deliver results in under 45 minutes is a game changer, dramatically reducing the time required for bioburden testing compared to traditional methods. This rapid turnaround can lead to faster decision-making processes, improved production efficiency, and potentially significant cost savings.
The performance of the device, meeting the stringent requirements of USP <1223>, ensures reliable and consistent results. This compliance is crucial for industries where regulatory standards are strict and non-negotiable.
The high sensitivity of the analyzer, with a Limit of Detection at 0.05 CFU/mL and a Limit of Quantification of 0.1 CFU/mL, allows for the detection of extremely low levels of microbial contamination. This capability is essential in situations where even minimal contamination can have serious consequences.
In conclusion, implementing an RMM, like the Sievers Soleil, can offer a comprehensive solution for rapid, accurate, and sensitive microbiological testing in high-purity water systems. Its capabilities have the potential to revolutionize quality control processes, enhance product safety, and improve operational efficiency in industries reliant on high-purity water.
Author Details
Meg Provenzano, Product Manager - Microbial Detection, Veolia Water Technologies & Solutions- Sievers Instruments
Meg Provenzano is the Product Manager for Sievers microbial detection instruments at Veolia Water Technologies & Solutions. She has over 10 years of experience in the bacterial endotoxin testing industry and has held several positions in Quality Control, Technical Support, and Product Management. Before joining Veolia, Meg was a Product Manager with Charles River Laboratories. She is customer-centric and enjoys hands-on problem-solving, whether for technical issues, assay assistance, or software. Meg holds a B.S. in Marine Science and Biology from Coastal Carolina University where she focused on Bottlenose Dolphin population research.
Publication Details
This article appeared in American Pharmaceutical Review: Vol. 27, No. 6Sept/Oct 2024Pages: 86-88
Subscribe to our e-newsletters
Stay up to date with the latest news, articles, and events. Plus, get special
offers from American Pharmaceutical Review delivered to your inbox!
Sign up now!